Depressed Jane

Bright white light therapy has been used to treat seasonal affective disorder (SAD) for more than 20 years. Although it remains a mainstay of treatment, in the past few years researchers have investigated ways to improve and refine light therapy, reports the November 2008 issue of the

Popularity: unranked [?]

Neuronetics, Inc. announced that a new health economic study evaluating the cost effectiveness of its NeuroStar TMS Therapy system in the treatment of depression was presented at the U.S. Psychiatric and Mental Health Congress in San Diego last week.

Popularity: unranked [?]

When anticipating pain, the brains of subjects with major depressive disorder appear to react more strongly, and appear to display altered functioning of the neural network that moderates pain sensitivity, according to an article released on November 3, 2008 in Archives of General Psychiatry, one of the JAMA/Archives journals. “Chronic pain and depression are common and often overlapping syndromes,” write the authors.

Popularity: unranked [?]

A new action plan to reduce suicide and self-harm in Wales was published today by the Welsh Assembly Government. The plan establishes a number of new initiatives and pulls together existing programmes to provide a strategic approach to suicide prevention in Wales. Statistics show that almost three-quarters of people in Wales who complete suicide are unknown to mental health services in the year prior to their death.

Popularity: unranked [?]

In the first-ever study of its kind, a team led by researchers at Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) report in November’s Psychiatric Services journal that Spanish-speaking Hispanics took longer to respond to medication for depression and were less likely to go into remission than English-speaking Hispanics.

Popularity: unranked [?]

There are few studies comparing the efficacy of short-term psychodynamic psychotherapy (STPP) and pharmacotherapy in major depressive disorder. A group of finnish investigators conducted a comparative study on the efficacy of STPP versus fluoxetine treatment in patients with major depressive disorder in a primary care setting.

Popularity: unranked [?]

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced results of a study in which Azilect® (rasagiline tablets) demonstrated selective MAO – B inhibition at the approved dose of 1mg. Non selective MAO inhibitors may have some contra indications with certain foods and drugs. These limitations are not associated with selective MAO inhibitors and therefore they can be broadly prescribed. Based on these positive results, Teva will work with the U.S.

Popularity: unranked [?]

The brains of individuals with major depressive disorder appear to react more strongly when anticipating pain and also display altered functioning of the neural network that modifies pain sensitivity, according to a report in the November issue of Archives of General Psychiatry, one of the JAMA/Archives journals. “Chronic pain and depression are common and often overlapping syndromes,” the authors write as background information in the article.

Popularity: unranked [?]

Substance abuse disorders (SUDs) and other psychiatric disorders are common among prison populations. A dual diagnosis (DD) refers to a co-existing SUD and any Axis I disorder, such as depression, schizophrenia, or social phobia. A new study has not only confirmed DD among prisoners in France, but has also found that it is a major risk factor for suicide.

Popularity: unranked [?]

With the days shortening toward winter, many people will begin to experience the winter blahs. For some, the effect can be devastating. About 6 percent of the U.S. population suffers from seasonal affective disorder, or SAD, a sometimes-debilitating depression that begins in the fall and continues through winter. Sufferers may even find it difficult to get out of bed in the morning.

Popularity: unranked [?]